HSBC Holdings’s Avidity Biosciences RNAM Stock Holding History

HSBC Holdings’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,729	Closed	-$2.36M	–	3181
2025 Q4	$2.36M	Buy	+32,729	New	+$2.11M	﹤0.01%	1497
2025 Q2	–	Sell	-13,177	Closed	-$383K	–	3210
2025 Q1	$383K	Sell	13,177 -4,342	-25%	-$135K	﹤0.01%	2227
2024 Q4	$507K	Buy	17,519 +9,230	+111%	+$386K	﹤0.01%	2168
2024 Q3	$368K	Sell	8,289 -5,436	-40%	-$236K	﹤0.01%	2206
2024 Q2	$561K	Sell	13,725 -1,380	-9%	-$39.6K	﹤0.01%	1922
2024 Q1	$385K	Sell	15,105 -3,520	-19%	-$55.2K	﹤0.01%	2250
2023 Q4	$169K	Buy	18,625 +5,767	+45%	+$38.5K	﹤0.01%	2513
2023 Q3	$80.7K	Buy	+12,858	New	+$111K	﹤0.01%	2581

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

HSBC Holdings's RNAM Position: Q1 2026 in Review

HSBC Holdings sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 32,729 shares — an estimated $2.36M sold.

HSBC Holdings first reported a position in RNAM in Q3 2023 and held it in 8 quarters. The position peaked at $2.36M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

HSBC Holdings reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
HSBC Holdings sold 32,729 Avidity Biosciences shares in Q1 2026, an estimated $2.36M.
HSBC Holdings first reported a position in Avidity Biosciences in Q3 2023 and held it in 8 quarters.
HSBC Holdings's Avidity Biosciences position peaked at $2.36M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.